The global sector for Behçet's disease therapeutics is observing a period of remarkable growth, driven by an increasing prevalence of the disease and advancements in treatment options. The need for effective therapies to manage the multifaceted symptoms of Behçet's disease is stimulating this development. Pharmaceutical companies are actively inv